
U.S. Department of Veterans Affairs








Cost Effective Therapies for Type 2 Diabetes

Meal planning and exercise should be primary elements of lifestyle interventions that are the cornerstone of every treatment plan.¹




ASCVD: indicators are age ≥55 years with coronary, carotid, or lower extremity artery stenosis >50% or LVH. CKD: eGFR 30-60 mL/min/1.73m² or UACR >30 mg/g, particularly UACR > 300 mg/g. HF: left ventricular ejection fraction <45%. *Agents shown to reduce ASCVD risk: SGLT-2 = Sodium-glucose co-transporter 2 inhibitor (empagliflozin, canagliflozin); GLP-1 = Glucagon-like peptide-1 agonist (inj. semaglutide, liraglutide, dulaglutide). GLP-1s have not been shown to lower heart failure risk (neutral outcome). Dapagliflozin has been shown to lower heart failure risk and CKD risk, but neutral for ASCVD. [†]Indicates referral to individual Criteria for Use. Do not combine a DPP-4 inhibitor with a GLP-1 agonist. ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; HF = heart failure.

In patients with cardiovascular disease, SGLT-2 inhibitors and GLP-1 agonists prevent cardiovascular events and reduce cardiovascular mortality. In addition, SGLT-2 inhibitors significantly reduce heart failure events in patients with reduced ejection fraction. Renal function declines slower when using SGLT-2 inhibitors and GLP-1 agonists with possibly a greater effect using SGLT-2 inhibitors.²



The cardiovascular and renal benefits of these agents are independent of their glucose-lowering effects.

Cardiac and Renal Benefits of SGLT-2 Inhibitors & GLP-1 Agonists²



*Kidney composite endpoint includes new-onset macroalbuminuria, sustained doubling of serum creatinine, or a 40% decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal death. **Worsening renal function includes worsening eGFR, end-stage kidney disease, or renal death. The beneficial effect of GLP-1 may be mostly from reducing macroalbuminuria.

Cost Considerations*

Drug Classes	\$	\$\$	\$\$\$	\$\$\$\$	\$\$\$\$\$
Sulfonylurea	[Glipizide] (Glucotrol®)				
	[Glimepiride] (Amaryl®)				
Biguanide	[Metformin] (Glucophage®)				
TZD	[Pioglitazone] (Actos®)		Rosiglitazone (Avandia®)		
DPP-4 Inhibitors		[Alogliptin] (Nesina®)			Linagliptin (Tradjenta®)
					Saxagliptin (Onglyza®)
					Sitagliptin (Januvia®)
SGLT-2 Inhibitors			[Empagliflozin] (Jardiance®)		Canagliflozin (Invokana®)
					Dapagliflozin (Farxiga®)
			(Jardiance)		Ertugliflozin (Steglatro®)
GLP-1 Agonists					[Liraglutide] (Victoza®)
					Dulaglutide (Trulicity®)
				[Semaglutide inj.]	Exenatide XR (Bydureon®)
				(Ozempic®)	Lixisenatide (Adlyxin®)
					Exenatide (Byetta®)
					Semaglutide oral (Rybelsus®)

Note: VA Formulary medications are bolded, []. Cost Symbols: \$ = < \$10; \$\$ = \$10-49.99; \$\$\$ = \$50-99.99; \$\$\$\$ = \$100-199.99; \$\$\$\$ = ≥ \$200. Cost is for a 30-days supply. *VA contracts for specific formulations of a particular drug should be followed.

REFERENCES

1. American Diabetes Association. Standards of medical care in diabetes - 2020. *Diabetes Care*. 2020;43(Suppl 1):S1-S207. 2. Zelniker TA, Wiviott SD, Raz I, et.al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. *Circulation*. 2019;139:2022–2031. <u>https://doi.org/10.1161/CIRCULATIONAHA.118.038868</u>.

This factsheet was created to be used as a tool for VA providers and is available to use from the VA PBM Academic Detailing Services SharePoint Site: <u>https://dvagov.sharepoint.com/sites/vhaacademicdetailing/SitePages/Home.aspx</u>